日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).

一项针对一线治疗后晚期食管胃癌患者的瑞戈非尼和紫杉醇 Ib/II 期研究 (REPEAT)

Stroes Charlotte I, Schokker Sandor, Khurshed Mohammed, van der Woude Stephanie O, Mathôt Ron Aa, Slingerland Marije, de Vos-Geelen Judith, Zucchetti Massimo, Matteo Cristina, van Dijk Erik, Ylstra Bauke, Thijssen Victor, Derks Sarah, Godefa Tesfay, Dijksterhuis Willemieke, Breimer Gerben E, van Delden Otto M, Verhoeven Rob Ha, Meijer Sybren L, Bijlsma Maarten F, van Laarhoven Hanneke Wm